We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+21.76%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.27B
AUM Growth
+$51.2M
Cap. Flow
-$77.3M
Cap. Flow %
-6.08%
Top 10 Hldgs %
71.44%
Holding
50
New
3
Increased
6
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$76.3M
2
ADVM
Adverum Biotechnologies
ADVM
+$22.8M
3
DYN icon
Dyne Therapeutics
DYN
+$13.6M
4
SLN
Silence Therapeutics
SLN
+$12.9M
5
RGLS
Regulus Therapeutics
RGLS
+$8.15M

Top Sells

Rank Stock Value
1
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$95.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$35.8M
3
ICVX
Icosavax, Inc. Common Stock
ICVX
+$26.9M
4
APGE icon
Apogee Therapeutics
APGE
+$11.2M
5
VRNA
Verona Pharma
VRNA
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTH
26
DELISTED
Genetron Holdings Limited ADS
GTH
$10.9M 0.86%
2,708,056
– –
IOBT
27
DELISTED
IO Biotech
IOBT
$10.7M 0.84%
6,173,439
– –
SVRA icon
28
Savara
SVRA
$1.13B
$10.4M 0.82%
2,088,323
– –
ZLAB icon
29
Zai Lab
ZLAB
$2.07B
$8.51M 0.67%
531,198
+119,521
+29% +$2.52M
DCTH icon
30
Delcath Systems
DCTH
$436M
$7.95M 0.62%
1,666,746
+811,555
+95% +$3.5M
RZLT icon
31
Rezolute
RZLT
$451M
$7.13M 0.56%
2,797,704
-445,138
-14% -$633K
CMPX icon
32
Compass Therapeutics
CMPX
$340M
$7.04M 0.55%
3,556,023
– –
TIL icon
33
Instil Bio
TIL
$49.2M
$6.74M 0.53%
624,338
-2
-0% -$22
QTTB icon
34
Q32 Bio
QTTB
$490M
$6.31M 0.5%
370,068
+349,509
+1,700% +$4.82M
BOLT icon
35
Bolt Biotherapeutics
BOLT
$7.59M
$4.93M 0.39%
176,065
– –
UNCY icon
36
Unicycive Therapeutics
UNCY
$143M
$4.79M 0.38%
347,015
– –
ALLK
37
DELISTED
Allakos
ALLK
$3.76M 0.3%
2,988,000
– –
ALGS icon
38
Aligos Therapeutics
ALGS
$29.3M
$3.48M 0.27%
141,881
– –
DBVT
39
DBV Technologies
DBVT
$843M
$2.03M 0.16%
270,888
– –
CDXS icon
40
Codexis
CDXS
$156M
$1.35M 0.11%
388,144
– –
WHWK
41
Whitehawk Therapeutics
WHWK
$201M
$1.19M 0.09%
509,572
– –
DTIL icon
42
Precision BioSciences
DTIL
$193M
$63.4K 0.01%
4,675
– –
APGE icon
43
Apogee Therapeutics
APGE
$10.2B
– –
-400,000
Closed -$11.2M
ARWR icon
44
Arrowhead Research
ARWR
$12.2B
– –
-137,411
Closed -$4.2M
IOVA icon
45
Iovance Biotherapeutics
IOVA
$1.94B
– –
-655,057
Closed -$5.33M
KALV
46
DELISTED
KalVista Pharmaceuticals
KALV
– –
-856,008
Closed -$10.5M
PHVS icon
47
Pharvaris
PHVS
$2.34B
– –
-285,000
Closed -$7.99M
RYZB
48
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-110,581
Closed -$6.87M
GRCL
49
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-9,546,485
Closed -$95.8M
ICVX
50
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-1,704,568
Closed -$26.9M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return

Vivo Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Vivo Capital held 50 positions worth $1.27B, up 4.2% from $1.22B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Vivo Capital withdrew a net $77.3M in Q1 2024, closing 8 positions and reducing 7 holdings. Its most notable exit was Gracell Biotechnologies Inc. American Depositary Shares, an estimated $95.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Sinovac Biotech, Ltd worth $76.3M.

  • Vivo Capital's largest Q1 2024 buy was Sinovac Biotech, Ltd: 11,800,000 shares worth $76.3M.
  • Vivo Capital added most to Dyne Therapeutics in Q1 2024, an estimated $13.6M increase.
  • Vivo Capital's biggest Q1 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $35.8M.
  • Vivo Capital fully exited Gracell Biotechnologies Inc. American Depositary Shares in Q1 2024, selling an estimated $95.8M.
  • Vivo Capital's ten largest holdings make up 71% of its $1.27B portfolio in Q1 2024.
  • Vivo Capital opened 3 new positions and closed 8 in Q1 2024.
  • Vivo Capital's portfolio value rose 4.2% quarter-over-quarter to $1.27B.

Based on Vivo Capital's 13F filing for Q1 2024, filed 22 Apr 2024.